“I am delighted to note the expansion plans of GeneSys Biologics Pvt Ltd for Genome Valley which will not only contribute to the growth of Hyderabad's biotech sector but also facilitate their ongoing collaboration with US-based Civica Rx. I would like to congratulate both companies as their efforts will contribute to addressing the Insulin affordability crisis and improve the lives of patients living with diabetes”: Minister KTR
IT and Industries Minister KTR met Civica and GeneSys leadership, including Mr. Tom Damratoski, Sr. Vice President, Biologics, Civica, and Mr. Allan Coukell, Sr. Vice President, Public Policy, Civica & President, Civica Foundation, as well as Mr. Venkat Reddy Yelma, Director, and Mr. Roopesh Kondrella, Director, from GeneSys Biologics.
Minister KTR expressed delight in learning that GeneSys, which has already invested approximately $50 million in Genome Valley, Hyderabad, has plans to invest an additional $50-60 million in setting up a new large scale recombinant bulk manufacturing facility (from fermentation to purified bulk insulin) for its insulin analogues.
GeneSys, a science-based biopharmaceutical company headquartered in Hyderabad, Telangana State, is focused on developing and manufacturing high-quality, affordable medications, including multiple insulin analog biosimilars. GeneSys currently employs about 250 personnel and anticipates adding approximately 300 jobs for its new facility.
GeneSys has partnered with Civica Rx, a U.S. non-profit generic drug company, to manufacture and distribute affordable insulin. Civica is dedicated to ensuring that essential medications are accessible and affordable for all patients.
Principal Secretary of IT and Industries Departments, Jayesh Ranjan, Special Secretary, Investment Promotion & NRI Affairs, E Vishnu Vardhan Reddy, Director of Telangana Life Sciences, Shakthi Nagappan were present at the meeting.
TAGS:
Who is the owner of GeneSys Biologics? What is the email address of GeneSys Biologics Pvt Ltd?
biopharma hub telangana, b-hub telangana,
0 Comments